137 related articles for article (PubMed ID: 24416562)
1. 3D conformal hypofractionated radical radiotherapy in early glottic cancer.
Amado AC; Bujor L; Monteiro Grillo I
Rep Pract Oncol Radiother; 2013 May; 18(5):261-4. PubMed ID: 24416562
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of acute/late toxicity and local recurrence in T1-T2 glottic carcinoma treated with accelerated hypofractionated 3D-conformal external beam radiotherapy (3D-CRT).
Kouloulias VE; Zygogianni A; Mosa E; Platoni K; Georgakopoulos J; Antypas C; Beli I; Tolia M; Maragoudakis P; Giotakis I; Papas Z; Psyrri A; Kelekis N; Kouvaris J
Radiol Oncol; 2013 Jun; 47(2):185-91. PubMed ID: 23801916
[TBL] [Abstract][Full Text] [Related]
3. Optimized treatment strategy of radiotherapy for early glottic squamous cell carcinomas: An initial analysis.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Naganawa S
Nagoya J Med Sci; 2017 Aug; 79(3):331-338. PubMed ID: 28878438
[TBL] [Abstract][Full Text] [Related]
4. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.
Le QT; Fu KK; Kroll S; Ryu JK; Quivey JM; Meyler TS; Krieg RM; Phillips TL
Int J Radiat Oncol Biol Phys; 1997 Aug; 39(1):115-26. PubMed ID: 9300746
[TBL] [Abstract][Full Text] [Related]
5. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated radiotherapy for early stage glottic cancer: efficacy of 3.5 Gy per fraction.
Lee TH; Lee JH; Kwon SK; Chung EJ; Wu HG
Radiat Oncol J; 2022 Jun; 40(2):120-126. PubMed ID: 35796115
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution.
Lee JW; Lee JE; Park J; Sohn JH; Ahn D
Radiat Oncol J; 2019 Jun; 37(2):82-90. PubMed ID: 31266289
[TBL] [Abstract][Full Text] [Related]
8. Study Protocol: Prospective Study of Concurrent Chemoradiotherapy with S-1 and Hypofractionated Radiotherapy for Outpatients with Early Glottic Squamous Cell Carcinomas.
Kimura K; Itoh Y; Okada T; Kubota S; Kawamura M; Nakahara R; Oie Y; Kozai Y; Takase Y; Tsuzuki H; Nishio N; Hiramatsu M; Fujimoto Y; Mizutani T; Hirakawa A; Naganawa S
Asian Pac J Cancer Prev; 2018 May; 19(5):1195-1199. PubMed ID: 29801401
[TBL] [Abstract][Full Text] [Related]
9. The impact of treatment time and smoking on local control and complications in T1 glottic cancer.
van der Voet JC; Keus RB; Hart AA; Hilgers FJ; Bartelink H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):247-55. PubMed ID: 9788401
[TBL] [Abstract][Full Text] [Related]
10. A multicenter survey of stage T1 glottic cancer treated with radiotherapy delivered in 2.25-Gy fractions in clinical practice: An initial 5-year analysis.
Itoh Y; Kubota S; Kawamura M; Nomoto Y; Murao T; Yamakawa K; Ishihara S; Hirasawa N; Asano A; Yanagawa S; Naganawa S
Nagoya J Med Sci; 2016 Dec; 78(4):399-406. PubMed ID: 28008195
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors.
Sakata K; Someya M; Hori M; Nakata K; Takagi M; Hareyama M
Strahlenther Onkol; 2008 Jul; 184(7):364-9. PubMed ID: 19016035
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study.
Moon SH; Cho KH; Chung EJ; Lee CG; Lee KC; Chai GY; Kang KM; Lee JY; Chung WK; Park WY; Kim JH
Radiother Oncol; 2014 Jan; 110(1):98-103. PubMed ID: 24161568
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiation fraction size on local control rates for early glottic carcinoma. A model analysis for in vivo tumor growth and radio-response parameters.
Ricciardelli EJ; Weymuller EA; Koh WJ; Austin-Seymour M; DeSautel MG; Laramore GE
Arch Otolaryngol Head Neck Surg; 1994 Jul; 120(7):737-42. PubMed ID: 8018326
[TBL] [Abstract][Full Text] [Related]
15. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
Ryu JK; Winter K; Michalski JM; Purdy JA; Markoe AM; Earle JD; Perez CA; Roach M; Sandler HM; Pollack A; Cox JD
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1036-46. PubMed ID: 12419429
[TBL] [Abstract][Full Text] [Related]
16. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of radiotherapy for T1a and T1bN0M0 glottic carcinoma.
Nomiya T; Nemoto K; Wada H; Takai Y; Yamada S
Laryngoscope; 2008 Aug; 118(8):1417-21. PubMed ID: 18528306
[TBL] [Abstract][Full Text] [Related]
18. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
19. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions.
Ermiş E; Teo M; Dyker KE; Fosker C; Sen M; Prestwich RJ
Radiat Oncol; 2015 Sep; 10():203. PubMed ID: 26395876
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.
Laskar SG; Baijal G; Murthy V; Chilukuri S; Budrukkar A; Gupta T; Agarwal JP
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e180-6. PubMed ID: 22862908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
